AI tool aims to predict breast cancer drug success, sparing patients unnecessary side effects

NCT ID NCT07689929

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study is developing an AI tool that analyzes tumor images, proteins, and patient data to predict whether a person with advanced HER2-positive or low-expression breast cancer will benefit from the targeted drug T-DXd. The goal is to avoid giving ineffective treatment, which can cause side effects and financial burden. Researchers will build and test the model using data from 900 patients across multiple hospitals.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
T-DXd (trastuzumab deruxtecan)
What this could lead to
If successful, this AI tool could help doctors identify which breast cancer patients are most likely to benefit from T-DXd, reducing unnecessary side effects and costs.
What could go wrong
This is an observational study using existing data, not a controlled trial. The AI model may not work as well in real-world settings or for all patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.